Merck has announced that it has agreed in principle to settle with plaintiffs’ lawyers in multi-district litigation over alleged side effects caused by its Fosamax anti-osteoporosis drug. In a statement Monday, the company said it is paying $27.7 million in the proposed settlement of all existing product liability cases alleging that Fosamax causes osteonecrosis of the jaw.
U.S. District Judge John Keenan (See Profile) of the Southern District of New York has tried a number of “bellwether” cases to set the parameters for settlement in some 1,200 federal cases pending over the drug, and the company has prevailed in most of those trials, with one notable exception: the $8 million verdict for plaintiff Shirley Boles in 2010 that was later reduced by the judge to $1.5 million (NYLJ, Sept. 1, 2011).
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
